欧州のセルベースアッセイ市場：分析と予測（2023年～2032年）

欧州のセルベースアッセイの市場規模は、予測期間の2023年～2032年にCAGR8.88%で拡大し、2023年の51億7,000万米ドルから2032年には111億2,000万米ドルに達すると予測さていれます。

セルベースアッセイ市場は、製薬業界の創薬努力と、従来の方法に対するこれらのアッセイの固有の利点に牽引されて急成長しています。ヒトの生理機能を模倣し、薬剤の有効性と毒性を早期に予測し、医療を個別化する能力が需要を後押ししています。この動向は、慢性疾患の増加や政府の支援策によってさらに増幅され、市場は大きく拡大する態勢を整えています。

欧州のセルベースアッセイ市場は、様々な要因が重なり、急成長を遂げています。効率的な創薬と個別化医療に重点を置く製薬・バイオテクノロジー分野の急成長が、こうした強力なツールへの需要を後押ししています。セルベースアッセイは、従来の動物モデルに代わる、よりヒトに関連したコスト効率の高い代替手段を提供し、薬剤候補の迅速なスクリーニングと作用機序のより深い理解を可能にします。このシフトは、学術研究への投資の増加や、ライフサイエンスのイノベーションを促進する政府の取り組みによって、さらに後押しされています。しかし、高い装置コストや厳しい規制の枠組みといった課題もあり、急速に発展するこの市場の可能性を最大限に引き出すには、戦略的パートナーシップと技術的進歩が必要です。

当レポートでは、欧州のセルベースアッセイ市場について調査し、市場の概要とともに、国別、企業別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 定義

第2章 調査範囲

第3章 調査手法

第4章 市場の概要

• 市場イントロダクション
  • セルベースアッセイのタイプ
• 産業におけるセルベースアッセイの現状と将来の状況
• セルベースアッセイ市場における新興技術と用途
• 現在の市場規模と成長の可能性、10億米ドル、2022年～2032年
• COVID-19によるセルベースアッセイ市場への影響
  • セルベースアッセイ企業への影響

第5章 業界考察

• 概要
• 欧州の法的要件と枠組み

第6章 市場力学

• 概要
• 影響分析
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第7章 競合情勢

• 競合情勢の概要
  • 主な発展
  • 製品の発売と拡張活動
  • 合併・買収活動
  • 相乗効果
  • ライセンスと契約の活動
• 市場シェア分析（2022年）
• 成長シェア分析（2021年～2022年）
  • 成長シェア分析（企業別）

第8章 欧州

• 概要
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の地域

第9章 企業プロファイル

List of Tables

• Table 1: Current and Future State of Cell-Based Assay in Industries
• Table 2: Utilizing the Potential of Cell-Based Assays: Novel Instruments and Methodologies in 2020-2021

List of Figures

• Figure 1: Impact Analysis of Drivers, Challenges, and Opportunities on the Cell-Based Assay Market
• Figure 2: Cell-Based Assay Market (by Region), 2022
• Figure 3: Cell-based Assay Market Methodology
• Figure 4: Primary Research Methodology
• Figure 5: Top-Down Approach (Segment-Wise Analysis)
• Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 7: Cellular Processes Utilized to Investigate the Impacts in Cell-Based Assays
• Figure 8: Emerging Technologies in the Cell-Based Assay Market
• Figure 9: Cell-Based Assay Market, $Billion, 2022-2032
• Figure 10: Impact of COVID-19 on Cell-Based Assay Companies
• Figure 11: Cell-Based Assay Market - Market Dynamics
• Figure 12: Total U.S. Life Sciences Venture Capital Funding, $Billion, 2016-2021
• Figure 13: Uses of Cell-based Assays in Regenerative Medicine
• Figure 14: Share of Key Developments and Strategies, January 2020 to March 2023
• Figure 15: Share of Product Launch and Expansion Activities (by Company), January 2020 to March 2023
• Figure 16: Share of Merger and Acquisition Activities (by Company), January 2020 to March 2023
• Figure 17: Share of Synergistic Activities (by Company), January 2020 to March 2023
• Figure 18: Market Share Analysis for Cell-Based Assay Market, 2022
• Figure 19: Growth-Share Analysis for Cell-Based Assay Market (by Company), 2021-2022
• Figure 20: Cell-Based Assay Market Snapshot (by Region)
• Figure 21: Cell-Based Assay Market (by Region), $Billion, 2022-2032
• Figure 22: Europe Cell-Based Assay Market, $Billion, 2022-2032
• Figure 23: Europe: Market Dynamics
• Figure 24: Europe Cell-Based Assay Market (by Country), $Billion, 2022-2032
• Figure 25: Germany Cell-Based Assay Market, $Billion, 2022-2032
• Figure 26: U.K. Cell-Based Assay Market, $Billion, 2022-2032
• Figure 27: France Cell-Based Assay Market, $Billion, 2022-2032
• Figure 28: Italy Cell-Based Assay Market, $Billion, 2022-2032
• Figure 29: Spain Cell-Based Assay Market, $Billion, 2022-2032
• Figure 30: Rest-of-Europe Cell-Based Assay Market, $Billion, 2022-2032
• Figure 31: Total Number of Companies Profiled
• Figure 32: Merck KGaA: Product Portfolio
• Figure 33: Lonza Group AG: Product Portfolio

“The Europe Cell-Based Assay Market Expected to Reach $11.12 Billion by 2032.”

Introduction to Europe Cell-Based Assay Market

The Europe cell-based assay market is expected to reach $11.12 billion by 2032 from $5.17 billion in 2023, at a CAGR of 8.88% during the forecast period 2023-2032. The Cell-Based Assay Market is surging, driven by the pharmaceutical industry's escalating drug discovery efforts and the inherent advantages of these assays over traditional methods. Their ability to mimic human physiology, predict drug efficacy and toxicity early, and personalize medicine fuels demand. This trend is further amplified by rising chronic disease prevalence and supportive government initiatives, fostering a market poised for significant expansion.

Market Introduction

The European cell-based assay market is experiencing a surge, fueled by a confluence of factors. The burgeoning pharmaceutical and biotechnology sectors, with their focus on efficient drug discovery and personalized medicine, are driving demand for these powerful tools. Cell-based assays offer a more human-relevant and cost-effective alternative to traditional animal models, allowing for rapid screening of drug candidates and a deeper understanding of their mechanisms of action. This shift is further bolstered by rising investments in academic research and government initiatives promoting life sciences innovation. However, challenges such as high instrumentation costs and stringent regulatory frameworks necessitate strategic partnerships and technological advancements to unlock the full potential of this rapidly evolving market.

Market Segmentation:

Segmentation 1: by Country

• U.K.
• France
• Italy
• Germany
• Spain
• Rest-of-Europe

Segmentation 2: by Company

• Merck KGaA
• Lonza Group AG

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe cell-based assay market is anticipated to witness growth during the forecast year 2023-2032. The advent of CRISPR/Cas9 technology has completely transformed gene studies and their functions by offering highly precise and user-friendly genome editing capabilities. CRISPR significantly streamlines the development of more intricate disease-related cell-based assays, enabling researchers to tackle complex questions and study heterogeneous diseases with more relevant and sophisticated assays.

Competitive Strategy: Key players in the Europe cell-based assay market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe cell-based assay market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

1. Definition

• 1.1. Inclusion and Exclusion Criteria

2. Research Scope

• 2.1. Key Questions Answered in the Report:

3. Research Methodology

• 3.1. Cell-Based Assay Market: Research Methodology
• 3.2. Primary Data Sources
• 3.3. Secondary Data Sources
• 3.4. Market Estimation Model
• 3.5. Criteria for Company Profiling

4. Markets Overview

• 4.1. Market Introduction
  • 4.1.1. Types of Cell-Based Assays
• 4.2. Current and Future State of Cell-Based Assays in Industries
• 4.3. Emerging Technologies and Applications in the Cell-Based Assay Market
• 4.4. Current Market Size and Growth Potential, $Billion, 2022-2032
• 4.5. COVID-19 Impact on Cell-Based Assay Market
  • 4.5.1. Impact on Cell-Based Assay Companies

5. Industry Insights

• 5.1. Overview
• 5.2. Legal Requirements and Frameworks in Europe

6. Market Dynamics

• 6.1. Overview
• 6.2. Impact Analysis
  • 6.2.1. Market Drivers
    • 6.2.1.1. Increase in Demand for Cell-Based Assay in Drug Discovery and Development
    • 6.2.1.2. Rise in Life Sciences Research Investments
    • 6.2.1.3. Technological Advancements
  • 6.2.2. Market Restraints
    • 6.2.2.1. High Cost
    • 6.2.2.2. Lack of Standardization
  • 6.2.3. Market Opportunities
    • 6.2.3.1. Increased Focus on Regenerative Medicine
    • 6.2.3.2. Emergence of Novel Gene Editing Technologies

7. Competitive Landscape

• 7.1. Competitive Landscape Overview
  • 7.1.1. Key Developments
  • 7.1.2. Product Launch and Expansion Activities
  • 7.1.3. Merger and Acquisition Activities
  • 7.1.4. Synergistic Activities
  • 7.1.5. License and Agreement Activities
• 7.2. Market Share Analysis (2022)
• 7.3. Growth-Share Analysis (2021-2022)
  • 7.3.1. Growth-Share Analysis (by Company)

8. Europe

• 8.1. Overview
• 8.2. Europe
  • 8.2.1. Germany
  • 8.2.2. U.K.
  • 8.2.3. France
  • 8.2.4. Italy
  • 8.2.5. Spain
  • 8.2.6. Rest-of-Europe

9. Company Profiles

• 9.1. Overview
  • 9.1.1. Merck KGaA
    • 9.1.1.1. Company Overview
    • 9.1.1.2. Role of Merck KGaA in the Cell-Based Assay Market
    • 9.1.1.3. Major Product: Key Specifications
    • 9.1.1.4. Key Competitors
    • 9.1.1.5. Analyst Perspective
  • 9.1.2. Lonza Group AG
    • 9.1.2.1. Company Overview
    • 9.1.2.2. Role of Lonza Group AG in the Cell-Based Assay Market
    • 9.1.2.3. Major Product: Key Specifications
    • 9.1.2.4. Key Competitors
    • 9.1.2.5. Analyst Perspective